Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTrilla-Fuertes, Lucía
dc.contributor.authorGhanem, Ismael
dc.contributor.authorGámez‑Pozo, Angelo
dc.contributor.authorMaurel, Joan
dc.contributor.authorG-Pastrián, Laura
dc.contributor.authorMendiola, Marta
dc.contributor.authorCapdevila Castillon, Jaume
dc.date.accessioned2021-10-22T14:43:22Z
dc.date.available2021-10-22T14:43:22Z
dc.date.issued2020-04
dc.identifier.citationTrilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastrián L, Mendiola M, et al. Genetic profile and functional proteomics of anal squamous cell carcinoma: proposal for a molecular classification. Mol Cell Proteomics. 2020 Apr;19(4):690–700.
dc.identifier.issn1535-9484
dc.identifier.urihttps://hdl.handle.net/11351/6458
dc.descriptionAnal squamous cell carcinoma; Molecular biology; Proteomics
dc.description.abstractAnal squamous cell carcinoma is a rare tumor. Chemo-radiotherapy yields a 50% 3-year relapse-free survival rate in advanced anal cancer, so improved predictive markers and therapeutic options are needed. High-throughput proteomics and whole-exome sequencing were performed in 46 paraffin samples from anal squamous cell carcinoma patients. Hierarchical clustering was used to establish groups de novo. Then, probabilistic graphical models were used to study the differences between groups of patients at the biological process level. A molecular classification into two groups of patients was established, one group with increased expression of proteins related to adhesion, T lymphocytes and glycolysis; and the other group with increased expression of proteins related to translation and ribosomes. The functional analysis by the probabilistic graphical model showed that these two groups presented differences in metabolism, mitochondria, translation, splicing and adhesion processes. Additionally, these groups showed different frequencies of genetic variants in some genes, such as ATM, SLFN11 and DST. Finally, genetic and proteomic characteristics of these groups suggested the use of some possible targeted therapies, such as PARP inhibitors or immunotherapy.
dc.language.isoeng
dc.publisherAmerican Society for Biochemistry and Molecular Biology
dc.relation.ispartofseriesMolecular & Cellular Proteomics;19(4)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectRecte - Càncer - Aspectes genètics
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshAnus Neoplasms
dc.subject.mesh/genetics
dc.titleGenetic profile and functional proteomics of anal squamous cell carcinoma: proposal for a molecular classification
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1074/mcp.RA120.001954
dc.subject.decscarcinoma de células escamosas
dc.subject.decsneoplasias del ano
dc.subject.decs/genética
dc.relation.publishversionhttps://doi.org/10.1074/mcp.RA120.001954
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Trilla-Fuertes L] Biomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain. [Ghanem I] Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain. [Gámez-Pozo A] Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. [Maurel J] Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain. [G-Pastrián L] Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. [Mendiola M] Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain. [Capdevila J] Servei d’Oncologia Mèdica, Vall Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid32107283
dc.identifier.wos000524532100011
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01310
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record